Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel
FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
"Incremental" step forward is sufficient for product to be labeled as deterring abuse by nasal, but not intravenous route, advisory committee members conclude.
US FDA's controversial approval of Dsuvia may prompt incoming House Democrats to pay special attention to commissioner's remarks on how agency reviews opioids.